Indication
In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
Medicine details
- Medicine name:
- selinexor (Nexpovio)
- SMC ID:
- SMC2674
- Pharmaceutical company
- Menarini Stemline
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 07 October 2024
- SMC meeting date:
- 03 September 2024
- Patient group submission deadline:
- 01 July 2024